Trial Profile
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Onilcamotide (Primary) ; Montanide ISA-51
- Indications Adenocarcinoma; Prostate cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms BRaVac
- Sponsors CHOSA Oncology
- 10 Feb 2023 According to a CHOSA Oncology media release, RhoVac AB changes name to CHOSA Oncology AB.
- 22 Aug 2022 This trial has completed in Denmark, as per European Clinical Trials Database record.
- 14 Aug 2022 This trial has been completed in Sweden (End Date: 2 June 2022) as per European Clinical Trials Database record